CBS 2019
CBSMD教育中心
English

急性冠脉综合征

科研文章

荐读文献

A Novel Circulating MicroRNA for the Detection of Acute Myocarditis Association of Silent Myocardial Infarction and Sudden Cardiac Death Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I Management of Myocardial Revascularization Failure: An Expert Consensus Document of the EAPCI Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial Incidence and Outcomes of Acute Coronary Syndrome After Transcatheter Aortic Valve Replacement The (R)Evolution of the CICU - Better for the Patient, Better for Education Phosphoproteomic Analysis of Neonatal Regenerative Myocardium Revealed Important Roles of CHK1 via Activating mTORC1/P70S6K Pathway

Original Research2016 Feb;172:1-8.

JOURNAL:Am Heart J. Article Link

Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)

Dasari TW, Hamilton S, Chen AY et al. Keywords: STEMI; non-eligibility for reperfusion therapy; PCI; hospital mortality

ABSTRACT


BACKGROUND - Reperfusion therapy is lifesaving in patients presenting with ST-segment elevation myocardial infarction (STEMI). Contemporary data describing the characteristics and outcomes of patients presenting with STEMI not receiving reperfusion therapy are lacking.


METHODS - Using the ACTION Registry-GWTG database, we examined 219,726 STEMI patients (January 2007-December 2013) at 721 percutaneous coronary intervention (PCI)-capable hospitals in United States. Clinical characteristics and in-hospital outcomes were stratified by those who underwent reperfusion (n = 188,200; 86%), those who did not undergo reperfusion with a reason for ineligibility (n = 27,179; 12%), and those without reperfusion but had no reason for ineligibility (n = 4,347; 2%).


RESULTS - Compared with STEMI patients receiving reperfusion therapy, the nonreperfusion groups were older, were more often female, and had higher rates of hypertension, diabetes, prior myocardial infarction, prior stroke, atrial fibrillation, and left bundle-branch block and heart failure on presentation. The major reason for reperfusion noneligibility was coronary anatomy not suitable for PCI (33%). Presence of 3-vessel coronary disease was more common in the nonreperfusion groups (with or without a documented reason) compared with reperfusion group (38% and 36% vs 26%, P < .001, respectively). In-hospital mortality was higher in patients not receiving reperfusion therapy with or without a documented reason compared with the reperfusion group (adjusted odds ratio [95% CI] 1.88 [1.78-1.99] and 1.37 [1.21-1.57], respectively).


CONCLUSION - Most patients with STEMI not receiving reperfusion therapy had a documented reason. Coronary anatomy not suitable for PCI was the major contributor to ineligibility. In-hospital mortality was higher in patients not receiving reperfusion therapy.


Copyright © 2015 Elsevier Inc. All rights reserved.